Double Bond Pharmaceutical has filed a Swedish patent application to protect the use of iron succinate for certain indications.

Earlier this year, a clinical study, a collaboration between Double Bond Pharmaceutical AB and Skellefteå University, showed that Inofer (iron succinate) significantly improves iron uptake, iron saturation and iron stores in patients with heart failure and iron deficiency.

DBP’s subsidiary Drugsson AB, has the distribution right for Inofer (iron succinate) in Sweden, Norway, Denmark and Finland.

"We are very pleased that the Inofer study, according to the plans, has shown the effect for a certain group of difficult-to-treat patients," comments Igor Lokot, CEO of Double Bond, - Now we will make sure to commercialize the invention in the relevant markets and support the Nordic market with a very potent product”.

More about clinical trials of Inofer: https://mb.cision.com/Main/12720/2974295/1151389.pdf

More about Drugsson AB: www.drugsson.com

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 29 of November 2019.

___________________________________________________________________ 

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:         SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Blog: http://blog.doublebp.com

Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.